Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
about
New perspectives on targeted therapy in ovarian cancerAntiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based MedicineInferring active and prognostic ligand-receptor pairs with interactions in survival regression models.Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cellsBevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinomaThe prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysisEndothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivoVascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Caregiver Burden in End-Stage Ovarian Cancer.SEOM Clinical Guideline in ovarian cancer (2016)The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.Cisplatin-, Doxorubicin-, and Docetaxel-Induced Cell Death Promoted by the Aqueous Extract of Solanum nigrum in Human Ovarian Carcinoma Cells.MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Effect of different anesthetic methods on cellular immune functioning and the prognosis of patients with ovarian cancer undergoing oophorectomy.The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors.Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Advances in ovarian cancer therapy.Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis.MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review.Primary peritoneal carcinosarcoma arising from the Douglas pouch: A case report
P2860
Q28082524-C32ABC83-463A-4F26-BA05-B28915E6D6C5Q33572395-5194394F-84EE-4DC2-BA36-39B28C889FB9Q35026818-8C44C8E2-9D14-4746-900F-99A7AF9DD7ADQ35538822-9E2A7503-CB7D-4EB5-9B87-6E1284FDC8E9Q35694417-1065B7A1-8612-47C0-A13B-95FBCF143D6AQ35920527-4B4420D2-B1F7-49BD-82E4-8675F3BC8C60Q36306542-D9B5F771-539D-4C37-8A55-554FA4862E74Q36414088-0D69362B-67B0-440F-A8D9-FE137582D292Q37158437-797ACBD0-9982-43DD-98F2-C004D4683FF2Q37201274-54E605B2-FAA8-4271-96CB-F6BDB53F309AQ37475168-7CD4684D-4253-4BEC-B5A4-3789D35C0D7BQ38282823-412BD637-504F-4FE5-B56B-3FD89C2D83E5Q38864663-80A90FDA-3FEF-4B5E-AF10-F68DA3803BE9Q38891975-95314322-5EAA-4119-9A96-AC283FA300C8Q41472874-A7112BF6-B47B-4681-8A0A-559FAE55E186Q42042730-427CAF98-B601-49E7-B616-2F334DD322E4Q42644504-42500934-39A8-48C8-A592-B3B42854C4CCQ42709077-2A12DA75-82AB-4647-8499-C6592DCFEBD6Q45711840-DB4CE16A-4831-4D8D-BE6C-466DA5C25204Q47861842-B8A20C25-2BD7-4E81-8874-182DB175D48FQ48104995-FE6C2064-E7E5-4706-BE8A-5BFD711D1CE7Q51795514-DAFD50E0-1A1C-4D4A-AA6B-EE5F2D190DB5Q53097666-9EECE85E-4D2C-425A-89DA-8814DB33F4EEQ53205827-FA4C2ACB-8C26-40C0-82EC-436721110ACCQ55346427-DCCD53BB-909F-455B-BB3A-2EF6154BD766Q57788555-82359A42-7753-4CC2-A397-CD1A214ED0D3
P2860
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Bevacizumab in combination wit ...... an cancer: a systematic review
@ast
Bevacizumab in combination wit ...... an cancer: a systematic review
@en
type
label
Bevacizumab in combination wit ...... an cancer: a systematic review
@ast
Bevacizumab in combination wit ...... an cancer: a systematic review
@en
prefLabel
Bevacizumab in combination wit ...... an cancer: a systematic review
@ast
Bevacizumab in combination wit ...... an cancer: a systematic review
@en
P2860
P921
P356
P1476
Bevacizumab in combination wit ...... an cancer: a systematic review
@en
P2093
Dimitrios Pectasides
P2860
P2888
P356
10.1186/1757-2215-7-57
P5008
P577
2014-05-19T00:00:00Z
P5875
P6179
1032719189